UK Markets open in 2 hrs

Neovacs S.A. (0W8U.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
0.3630+0.3528 (+3,451.86%)
At close: 4:54PM BST

Neovacs S.A.

3-5, Impasse Reille
Paris 75014
France
33 1 53 10 93 00
http://www.neovacs.fr

Sector(s)
Industry
Full-time employees15

Key executives

NameTitlePayExercisedYear born
Prof. Daniel ZaguryFounder, Chairman of Scientific Research Committee & Director11kN/AN/A
Mr. Vincent SerraScientific & Operational Director197.64kN/A1970
Mr. Hugo BrugiereChairman, GM & CEON/AN/AN/A
Mr. Alexandre CourtouxAdmin. & Financial DirectorN/AN/AN/A
Charlene MassonCorp. Communication & Investor RelationsN/AN/AN/A
Ms. Valerie Salentey Ph.D.Head of Regulatory AffairsN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

Corporate governance

Neovacs S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.